Sponsor:
Stephen Shiao
Code:
NCT07015853
Conditions
TNBC - Triple-Negative Breast Cancer
Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pembrolizumab
Radiotherapy
Axatilimab
Brief summary:
Conditions
TNBC - Triple-Negative Breast Cancer
Breast Cancer
Study ID
NCT07015853
Start date
Dec, 2026
Status verified date
Nov, 2026
Completion date
Dec, 2033
Anticipated
Primary completion date
Dec, 2033
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
34 participants
Anticipated
Intervention Model
Single group
Primary purpose
Treatment
Arms
experimental: Pembrolizumab, Radiotherapy, Axatilimab
Interventions
Pembrolizumab
Radiotherapy
Axatilimab
Primary outcome measure
Central contacts
Locations
Cedars-Sinai Medical Center
Recruiting
Los Angeles, California, United States, 90048
Contacts
Principal Investigator:
Stephen L Shiao, MD, PhD
Sponsor
Stephen Shiao
Last update posted
Nov 16, 2026
Last verified
Nov, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-17. This information was provided to ClinicalTrials.gov by Stephen Shiao on 2026-11-16. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.